Wenxiang Ji

Sep 4, 2024 | science.org | Anjali Singh |Xue Zhang |Zhuo Chen |Wenxiang Ji

Editor’s summaryNon–small cell lung cancer can be treated with anti–programmed death 1/ligand 1 (anti–PD-1/L1); however, biomarkers for response are imprecise. Here, Chen et al. evaluate the loss of protein tyrosine phosphatase receptor type T (PTPRT) as a predictor of response to anti–PD-1/L1 therapy. They show in mouse models that PTPRT-deficient tumors rely on the STING pathway to respond to anti–PD-1 therapy, and this study can help stratify patients who would benefit from this therapy.